Hirsutism: Management and Therapeutic Options

    January 2001
    Susan R. Davis, Jane Tran
    TLDR Most excessive hair growth is due to idiopathic hirsutism or PCOS; treatment starts with cosmetic methods and drugs like cyproterone acetate or spironolactone, with results in 6-12 months.
    The document from 23 years ago discussed the management and therapeutic options for hirsutism, a condition characterized by excessive hair growth. The majority of patients with this condition either had idiopathic hirsutism or features of polycystic ovary syndrome. The initial treatment involved cosmetic measures such as bleaching, shaving, and waxing. It was noted that it generally took 6-12 months of drug treatment for improvements to be noticed. The first line of drug therapy included cyproterone acetate or spironolactone, either alone or in combination with an oral contraceptive pill.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 24 results

      community DHT levels after 4 weeks of Fina and 8 weeks of Fina + 4 weeks of Duta

      in Update  36 upvotes 5 years ago
      The user reported early stage diffuse hair thinning and increased DHT levels after 4 weeks on Finasteride and 8 weeks on Finasteride plus 4 weeks on Dutasteride, despite the medications being authentic and stored properly. They are considering increasing their Dutasteride dosage due to the lack of side effects and are unsure if the treatment is helping their hair.

      community AA and Hirsutism but T levels are normal

      in Female  8 upvotes 3 years ago
      27-year-old female experiences aggressive hair thinning and hirsutism despite normal testosterone levels. Spironolactone and 2% minoxidil were ineffective; high DHEA sulfate levels may be the cause.

      community No, Finasteride as a treatment for MPB was not an "accident"

      in Research/Science  105 upvotes 3 years ago
      Finasteride was intentionally developed to treat BPH and later approved for male pattern baldness (MPB) due to its 5AR inhibition effects. The delay in MPB approval was due to concerns about off-label use for female hirsutism and the prioritization of treating a more debilitating condition.

      community Coegin Pharma to release Follicopeptide (FOL005) by Q2 2025

      in Treatment  117 upvotes 2 months ago
      Follicopeptide (FOL005) by Coegin Pharma will launch as a cosmetic hair growth treatment by Q2 2025, showing similar efficacy to finasteride. Users discuss the benefits and skepticism of releasing hair loss treatments as cosmetics rather than drugs.

      community Does low HGH leading to hairloss?

      in Research/Science  13 upvotes 9 months ago
      The user experiencing diffuse hair loss is using various treatments including RU58841, finasteride, minoxidil with tretinoin, anti-hair loss shampoo, and microneedling, and is considering adding peptides TB500, BPC157, and GHK-Cu. They have low growth hormone levels and are questioning its impact on hair loss, while another user suggests androgenic alopecia and androgens are likely the main cause of hair loss.

    Related Research

    10 / 10 results